Myriad Genetics, Inc. (MYGN)

Myriad Genetics' stock price has experienced significant fluctuations over the past six months, declining by 64.37% between October 22, 2024, and October 21, 2025. In May 2025, the company missed revenue expectations, leading to a stock price drop. In February 2025, Myriad Genetics missed Q4 CY2024 sales targets. In August 2025, the company reported strong Q2 CY2025 results, causing the stock to jump. In September 2025, Myriad Genetics announced the publication of Precise MRD clinical data and a collaboration with SOPHiA GENETICS. In October 2025, the company added genes to its Foresight Universal Plus Panel and is scheduled to release its Q3 2025 financial results.

Myriad Genetics experiences demand seasonality for its products and services, with gross margins fluctuating quarterly due to product mix, pricing trends, and seasonality. Q1 gross margins are typically lower than Q4 gross margins and are expected to increase throughout the year. Analysts' projections suggest potential demand challenges with decelerating revenue growth.

Myriad Genetics, Inc. is a molecular diagnostic testing and precision medicine company operating in the Healthcare sector, focusing on Molecular Diagnostics, Biotechnology, Diagnostics & Research, and In Vitro & in Vivo Diagnostic Substances industries. The company develops and commercializes molecular diagnostic tests to assess disease risk, guide treatment decisions, and monitor disease progression. Major products include the myRisk Hereditary Cancer Test, GeneSight Psychotropic Test, Prolaris, Endopredict, and Precise MRD, along with other offerings like carrier screens, fetal sex determination, and tumor testing.

Myriad Genetics is headquartered in Salt Lake City, Utah, and operates manufacturing facilities within the United States. The company has an international presence through its Myriad International and Myriad Autoimmune subsidiaries, with offices and distributors across Europe, Asia Pacific, and Latin America.

Myriad Genetics has highlighted its commitment to expanding access to genetic and tumor genomic testing. However, the company's reputation has been impacted by securities fraud investigations following Q1 2025 financial results, which revealed a decline in revenue due to reduced coverage of the GeneSight test by UnitedHealthcare, leading to a significant drop in the company's stock price.

Myriad Genetics has a diverse ownership structure, with institutional investors holding the majority of shares (91.28%), followed by insiders (8.72%), and retail investors. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, and iShares Core S&P Small-Cap ETF (IJR). Paul J. Diaz is the largest individual shareholder. Insider selling has been observed over the past year.